	US 12,187,797 B2
	SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof
Sandip Panicker, South San Francisco, CA (US); Adam David Rosenthal, South San Francisco, CA (US); and Eileen Lingshu Rose, South San Francisco, CA (US)
Assigned to Electra Therapeutics, Inc., South San Francisco, CA (US)
Filed by Electra Therapeutics, Inc., South San Francisco, CA (US)
Filed on Feb. 28, 2024, as Appl. No. 18/590,865.
Application 18/590,865 is a continuation of application No. 17/923,778, previously published as PCT/US2021/031605, filed on May 10, 2021.
Claims priority of provisional application 63/022,309, filed on May 8, 2020.
Prior Publication US 2024/0239888 A1, Jul. 18, 2024
Int. Cl. A61K 39/395 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 37/06 (2018.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

29 Claims

1. An antibody that is specific for one or more of SIRPα and SIRPβ1, and is specific for SIRPγ, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprise a combination of six complementarity determining regions (CDRs), wherein the CDR combination comprises the amino acid sequences of:

a. SEQ ID NO: 5, SEQ ID NO: 23, SEQ ID NO: 36, SEQ ID NO: 54, SEQ ID NO: 70, and SEQ ID NO: 86; or

b. SEQ ID NO: 16, SEQ ID NO: 31, SEQ ID NO: 47, SEQ ID NO: 62, SEQ ID NO: 79, and SEQ ID NO: 97.